

Daiichi Sankyo, Inc.'s LinkedIn Community Guidelines

Welcome to the Daiichi Sankyo US LinkedIn page and thank you for joining our community. We appreciate the opportunity to hear from you on our US LinkedIn page where we often share stories about Daiichi Sankyo news and activities. If you comment or ask questions, please follow these Community Guidelines along with <u>LinkedIn's User Agreement</u> to ensure everyone who visits this page has the best experience possible.

As a pharmaceutical company, we work in a highly-regulated industry with unique legal considerations. Therefore, we are not permitted to engage in sensitive topics or discussions about our products, other companies' products or treatment options on LinkedIn. These discussions are best held in private with a health care professional.

Because of these regulations, we may delete or not respond to comments on the Daiichi Sankyo US LinkedIn Page that:

- Name our or other companies' products
- Offer health or medical advice
- Include profanity, defamatory, libelous, offensive, abusive, discriminatory harassing, or demeaning content, including images, videos, and links
- Are disparaging, threatening, condone violence or illegal behavior
- Contain personal information, such as the names of individuals, email addresses, phone numbers, personal photos, or videos
- Contain proprietary, confidential, sensitive, or non-public information
- Violate copyright or intellectual property rights
- Are commercial in nature with an intent to sell products and services, or recruit fans and followers to other social communities
- Contain information that is false, inaccurate, or misleading
- Are excessively repetitive and/or disruptive to the community (SPAM); or posts that don't follow <u>LinkedIn's User Agreement</u>.

Please be aware that followers who violate the above rules may be blocked from our LinkedIn page. In this case, the user would no longer be able to follow our news or comment on our posts. Content from LinkedIn profiles that the US Daiichi Sankyo page likes, or shares, are not an indication of a Daiichi Sankyo endorsement of these profiles. Nor is it an indication that we are engaged in a business relationship with the content authors. Daiichi Sankyo is not responsible for and does not assume any liability for any such third-party content. Nothing provided on these channels constitutes an offer or invitation to invest or deal in Daiichi Sankyo securities.

Reporting Adverse Reactions

If you believe you have experienced any medical side effects from a Daiichi Sankyo product, please consult your physician, pharmacist, or other healthcare professional immediately. We encourage you to report a product issue or product question to <u>our Contact Center</u> at 1-877-4 DS-PROD (1-877-437-7763). Health professionals, consumers and patients can voluntarily report observed or suspected adverse events for human medical products to FDA at www.fda.gov/medwatch or by calling 1-800-FDA-1088.

It is not recommended to share any specific data concerning your personal health on LinkedIn, other social media sites. Please be aware that Daiichi Sankyo may need to contact any individual who includes a post with details related to any medical side effects or product issues to find out more information. Posts with sensitive personal health information may be removed from the Daiichi Sankyo US LinkedIn page due to legal obligations concerning drug safety reporting.

Using and storing personal identifying information

Daiichi Sankyo will not disclose or share personal identifying information on its LinkedIn account unless we have obtained proper consent. We do not store or use your LinkedIn profile unique ID, email or other personal identifying information. However, in the case of reporting a side effect or product issue, we will need to store and use personal identifying information, such as your name, location, health-related information or similar, in accordance with applicable laws. This information is required to be submitted to the Daiichi Sankyo Pharmacovigilance and Patient Safety department and/or regulatory authorities. We are also required to store your personal identifying information for auditing purposes.

In some instances, Daiichi Sankyo may choose to use third-party service providers to help us manage comments and messages, which means that they too would have access to any personal identifying information you share with us. Such third-party service providers are contractually bound and trained to ensure an adequate protection and security of your personal identifying information.

Please note that LinkedIn also has access to information you share with us. For more details read the LinkedIn Privacy Policy.

Thank you for reading and being a part of the US Daiichi Sankyo LinkedIn community.